Key facts
- It has raised $8.4M across 1 recorded rounds; the latest was Merger/Acquisition in Jan 2025.
- Decoy Therapeutics has filed 2 Form Ds with the SEC, most recently Jul 2025 ($1.2M sold to 20 investors).
- Status: Acquired/Merged (Operating Subsidiary).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Decoy Therapeutics
Funding rounds
1 roundsAbout Decoy Therapeutics
Developer of immunotherapy products designed for addressing cancer treatment challenges. The company leverages proprietary technology to develop therapies that target immune system pathways, incorporating innovative approaches to enhance efficacy and minimize side effects, enabling doctors with access to advanced treatment options while improving overall outcomes in oncology care.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2020
- Employees
- 7
- Website
- decoytx.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Decoy Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Decoy Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Decoy Therapeutics in its N-PORT filings yet. We sweep new filings monthly.